The content discusses a recent ruling by the U.S. Court of Appeals for the Federal Circuit (CAFC) regarding the Vieths’ patent claims for a method of administering vitamin D. The court upheld the Patent Trial and Appeal Board’s (PTAB) decision to invalidate those claims, asserting that the Vieths did not adequately develop several arguments during prior proceedings.
Key Points:
-
Invalidation of Patent Claims: The CAFC affirmed the PTAB’s ruling that found the Vieths’ methods for administering vitamin D obvious based on prior art disclosures; specifically, a German textbook that discussed a method using medium-chain triglycerides (MCT).
-
Change in Position: The CAFC noted that the Vieths’ argument concerning the specifics of the composition of Vigantol was a change in position rather than a continuation of their earlier arguments, leading to the forfeiture of this claim.
-
Nexus Issue: The court addressed the Vieths’ claims of industry praise for their products but found that non-infringing uses stated on product labels undermined any presumed entitlement to establish a link (nexus) to their patent.
-
Prior Art Considerations: The PTAB found that the methods disclosed in cited studies provided sufficient motivation to combine techniques for effective vitamin D delivery, and the CAFC supported this conclusion.
-
Commercial Success and Need: The court concluded that the Vieths failed to prove a definitive link between their claims and the commercial success of related products, citing prior art that diminished the novelty of their claims.
Overall, the CAFC’s ruling serves as a crucial reminder about the importance of properly developing patent arguments and the evidentiary standards needed to establish non-obviousness in the face of similar prior art.
